Protect Yourself While There’s Still Time …

The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.

4 simple steps to protect your privacy and money before it’s too late.

Vincent Aurentz Biography and Net Worth

VP of Arena Pharmaceuticals

Vincent E. Aurentz has served as our Executive Vice President and Chief Business Officer since August 2016. Mr. Aurentz has over 30 years of experience in the biopharmaceutical industry. Previously, he was the Chief Business Officer of Epirus Biopharmaceuticals, Inc. from November 2015 to July 2016. Prior to that, Mr. Aurentz served as President and was a member of the Board of Directors of HemoShear Therapeutics, LLC from July 2013 to November 2015, where he oversaw discovery programs, scientific, and business development efforts including R&D collaborations with global pharmaceutical companies. Prior to joining HemoShear Therapeutics, Mr. Aurentz was Executive Vice President and member of the Executive Management Board at Merck KGaA (Merck Serono S.A.) where he directed R&D programs, portfolio strategy and headed all deal activity and venture investments. Mr. Aurentz is a former Executive Vice President at Quintiles and a Co-founder and Managing Director of a venture capital and advisory business. He was a partner with CSC Healthcare, the life sciences strategic management consulting division of Computer Sciences Corporation, after starting his career and working for 8 years at Andersen Consulting (now Accenture). In July 2016, Epirus filed a voluntary Chapter 7 petition in the United States Bankruptcy Court for the District of Massachusetts. Mr. Aurentz serves on the Board of Directors for Longboard Pharmaceuticals, Inc., a pharmaceutical company developing therapeis to treat rare neurological diseases. Mr. Aurentz received a B.S. in mathematics from Villanova University. Provided by Tagnifi.

What is Vincent Aurentz's net worth?: The estimated net worth of Vincent Aurentz is at least $2.95 million as of February 16th, 2021. Mr. Aurentz owns 29,500 shares of Arena Pharmaceuticals stock worth more than $2,949,705 as of April 26th. This net worth evaluation does not reflect any other investments that Mr. Aurentz may own. Additionally, Mr. Aurentz receives a salary of $692,820.00 as VP at Arena Pharmaceuticals. Learn More about Vincent Aurentz's net worth.
How old is Vincent Aurentz?: Mr. Aurentz is currently 54 years old. There are 1 older executives and no younger executives at Arena Pharmaceuticals. The oldest executive at Arena Pharmaceuticals is Mr. Michael E. Paolucci, Exec. VP of HR, who is 62 years old. Learn More on Vincent Aurentz's age.
What is Vincent Aurentz's salary?: As the VP of Arena Pharmaceuticals, Inc., Mr. Aurentz earns $692,820.00 per year. The highest earning executive at Arena Pharmaceuticals is Mr. Amit D. Munshi M.B.A., Pres & CEO, who commands a salary of $1,220,000.00 per year. Learn More on Vincent Aurentz's salary.
How do I contact Vincent Aurentz?: The corporate mailing address for Mr. Aurentz and other Arena Pharmaceuticals executives is 6154 Nancy Ridge Drive, San Diego CA, 92121. Arena Pharmaceuticals can also be reached via phone at (858) 453-7200 and via email at [email protected]. Learn More on Vincent Aurentz's contact information.
Has Vincent Aurentz been buying or selling shares of Arena Pharmaceuticals?: Vincent Aurentz has not been actively trading shares of Arena Pharmaceuticals during the last quarter. Most recently, Vincent Aurentz sold 2,524 shares of the business's stock in a transaction on Tuesday, February 16th. The shares were sold at an average price of $85.00, for a transaction totalling $214,540.00. Following the completion of the sale, the vice president now directly owns 29,500 shares of the company's stock, valued at $2,507,500. Learn More on Vincent Aurentz's trading history.
Who are Arena Pharmaceuticals' active insiders?: Arena Pharmaceuticals' insider roster includes Vincent Aurentz (VP), Christopher Cabell (CMO), Jayson Dallas (Director), Robert Lisicki (EVP), Amit Munshi (CEO), Tina Nova (Director), and Manmeet Soni (Director). Learn More on Arena Pharmaceuticals' active insiders.

Vincent Aurentz Insider Trading History at Arena Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/16/2021	Sell	2,524	$85.00	$214,540.00	29,500
6/2/2020	Sell	25,000	$65.00	$1,625,000.00	10,000
9/9/2019	Sell	65,000	$50.72	$3,296,800.00	25,000

Vincent Aurentz Buying and Selling Activity at Arena Pharmaceuticals

Arena Pharmaceuticals Company Overview

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.

Today's Range

Now: $99.99

$99.99

50 Day Range

MA: $97.65

$93.13

$99.99

2 Week Range

Now: $99.99

$45.50

$100.00

Volume

107 shs

Average Volume

1,561,326 shs

Market Capitalization

$6.17 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.55

Protect Yourself While There’s Still Time …

From Weiss Ratings | Ad